Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nucleix Ltd
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
IV BioHoldings CEO Marty Keiser connects data, technology, capital and people to create start-ups focusing on liquid biopsy programs.
The new money will help the company advance its unique EpiCheck technology for detecting cancer-specific-changes to DNA called methylation.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.